congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
Dato-DXd, T-DXd, Valemetostat
ASCO 2024 | May 31 - June 4, 2024
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody-drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
Poster
Other/Multi
AMCP Nexus 2024 | October 14-17, 2024
A retrospective real-world evaluation of docetaxel-based treatments after standard of care (SOC) for patients with non-squamous (NSQ) advanced non-small cell lung cancer (aNSCLC)
Poster
Dato-DXd
ESMO 2024 | September 13-17, 2024
Dato-DXd vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: Results from TROPION-Lung01
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) in Chinese patients with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study
Poster
Dato-DXd
ELCC 2024 | March 20-23, 2024
Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC) – nonsquamous (NSQ) histology in the phase 3 TROPION-Lung01 Trial
Poster
Dato-DXd
ASCO 2024 | May 31 - June 4, 2024
Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab with or without platinum chemotherapy as first-line therapy for advanced non-small cell lung cancer (NSCLC); subgroup analysis from TROPION-Lung02
Mini-Oral
Dato-DXd
ESMO Asia 2023 | December 1-3, 2023
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPION-Lung01
Oral
Dato-DXd
WCLC 2024 | September 7-10, 2024
Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: Final overall survival from TROPION-Lung01
Poster
Other/Multi
NCCN 2024 | April 5-7, 2024
Determinants of quality of life and optimism in patients with EGFR-mutated advanced
non-small cell lung cancer
Poster
Dato-DXd
ACoP15 | November 10-13, 2024
Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer